President Trump signed an executive order this past week ordering federal drug authorities to reclassify cannabis as a less addictive substance with medical benefits. While it will have some impact on research and business expenses, Connecticut consumers may not see much change.
Ben Zachs, who runs Fine Fettle cannabis dispensaries and cultivation said that while the change is "much deserved and needed," it won't significantly affect Connecticut's cannabis industry.
"From a day to day operations standpoint, it is status quo," he said. "The impact to research and understanding will be immense. We see thousands every day gaining immense benefit from cannabis and now it will be better quantified and measured. We also hope that this begins to codify a change in sentiment we face daily. This has been a long time coming and to now have the federal government push it to the finish line is incredibly impactful."
Trump signed an executive order Thursday directing the U.S. Drug Enforcement Agency to reclassify cannabis from Schedule I, reserved for substances with highly addictive potential and no medical benefit, to Schedule III, a category of substances with little to no addictive potential and some medical applications.
Read more at CT Insider
